Navigation Links
Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Date:4/30/2008

WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced that it has appointed Eliot M. Lurier, CPA, as its Chief Financial Officer.

Lewis H. Bender, Chief Executive Officer of Interleukin Genetics, Inc., commented on the appointment, "Eliot is an innovative and experienced senior financial executive with an entrepreneurial spirit and a proven record of achievement in managing growth for publicly traded companies. The addition of Eliot to the senior management team provides financial management and operational skills that we need to develop and grow our business."

Mr. Lurier, age 50, has more than 25 years of financial management experience, primarily in the life sciences industry. Prior to joining Interleukin Genetics, he was Vice President, Finance and Administration and Chief Financial Officer of Nucryst Pharmaceuticals (Nasdaq: NCST, TSX: NCS), where he successfully completed a $45 million IPO within 6 months of joining the company and was responsible for SEC reporting and the implementation of Sarbanes-Oxley requirements. Previously, he served as Chief Financial Officer and Chief Operating Officer for Bridge Pharmaceuticals, Inc., where he established all policies for managing business operations.

Mr. Lurier commented, "I am very excited about the opportunity to join Interleukin Genetics. The Company is well positioned to become a leading provider of preventive consumer products and genetic tests for sale to the emerging personalized health market. I look forward to helping the Company communicate the value of such tests to the investment community."

Prior to joining Bridge Pharmaceuticals, Inc., Mr. Lurier held a number of senior-level financial positions i
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
2. Interleukin Genetics Retains Top Life Science Communications Firms
3. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
6. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
7. Interleukin Genetics Announces Management and Board Appointments
8. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
9. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
10. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
11. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...SANDIEGO,Nov.25/PRNewswire-FirstCall/--ArdeaBiosci...Quart,Pharm.D.,presidentandchiefexecutiveofficer,w...ference. , ,Presentationdetailsareasfollows:,Pip...ay,December1,2009,Time:2:00p.m.EasternTime,Locatio...,http://www.corporate-ir.net/ireye/,target=,_blan...
(Date:11/24/2009)... The New York investment bank KTA...NEU) has agreed an AU$6.7 mil convertible note pri... The private placement was arranged by KTA Capital.... , New York (PRWEB) Nove...nt bank KTA Capital, LLC ("KTA Capital")...
(Date:11/24/2009)...ST.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-Aldri...ASDAQOMXconferenceonTuesday,December1stat1:45PMGMT...aliveaudiobroadcastovertheInternetavailableat htt...canclickthe"Webcast"icontoaccessthisfile. ,, ...ienceandHighTechnologycompany.Itschemicalandbioche...
(Date:11/24/2009)...SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/--Neur...yfocusedondevelopingandcommercializingnovelpainman...PresidentandChiefExecutiveOfficer,isscheduledtopre...e,tobeheldDecember1-2,2009atTheNewYorkPalaceHoteli...eri,ChiefFinancialOfficer,willbeavailabletorespond...
Breaking Biology Technology:Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
...njection sales surpassed $765 ...y review by FDA in newly diagnosed multiple ...2008 -, CAMBRIDGE, Mass., Feb. 7 Millennium,Phar...2007 non-GAAP net,income of $86.9 million and GAAP...eeded the Company,s 2007 financial guidance, drive...
...rvices Revenues, Lower Expenses, POWAY, Calif., F...ding provider of medical diagnostic imaging system...nd imaging centers, today,reported narrower losses...,higher annual revenues and lower operating expens...uarter were $18.8 million, up nine,percent from $1...
...ts have broken a technological barrier by making t...erased and rewritten in a matter of minutes. , Th...pecial eyewear are the first updatable three-dime... making them ideal tools for medical, industrial a... awareness." , "This is a new type of device, not...
Other Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months 2Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months 3Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months 4Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months 5Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months 6Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months 7UA optical scientists add new, practical dimension to holography 2UA optical scientists add new, practical dimension to holography 3
(Date:11/25/2009)... State University assistant professors recently re...n (NSF) to continue research beneficial to underst...0,000. , Christopher Blackwood, assistant profes...awarded grants to support two separate research pr...Litter Decomposer Communities and Functions from t...
(Date:11/24/2009)...cience is opening new doors to understanding how s...hearing of a marine mammal or if they hear it at ...-ray scanners that NASA uses to detect flaws in th...ow allowing scientists to peek inside the giant he...ree-dimensional replicas of a whale,s hearing anat...
(Date:11/24/2009)... and the American College of Medical Toxicology (A...e publication of the Journal of Medical Toxicolog...ing in March 2010. It was previously published by...ournal of Medical Toxicology , an international, p...e science and practice of medical toxicology. The...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Arizona American Water and Salvation Army Offer Aid on Hottest Days 47550 1Arizona American Water and Salvation Army Offer Aid on Hottest Days 47550 2PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 1PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 2PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 3PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 5PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 61 in 3 U S Kids Lack Nearby Trauma Care 47546 11 in 3 U S Kids Lack Nearby Trauma Care 47546 2
...tic infection common in China and Southeast Asia c...opulations, according to research published in PLo...ous species affects some 200 million people worldw...uding liver failure. Steven Riley of the Universit...n patterns of the parasitic worm Schistosoma japon...
... from the University of Bristol shows that by supp... in wound cells, wounds can heal faster and reduce...r wound victims but also for people who suffer org...ery. , When skin is damaged a blood clot forms an...amage, leading to scarring. Scarring is a natural ...
...se is available in French and German . , , Re... the EPFL in Switzerland have developed a novel me...lengths used in typical medical and industrial ima...detail than ordinary x-ray radiographs and could b...st cancer or Alzheimers disease, to identify explo...
Other Biology News:Controlling schistosomiasis: buffalo or snails? 2Skin care: new research into scar-free healing 2New technology sharpens X-ray vision 2
Anti-Yersinia pestis Monoclonal Antibody, Unconjugated from ViroStat Inc.
Rabbit Anti-Olfactory Receptor LS189744 Polyclonal Antibody, Unconjugated from Abcam
Anti-Varicella-zoster Virus, Nucleocapsid Protein Monoclonal Antibody, Unconjugated from CHEMICON
Mouse Anti-Zeralenone Monoclonal Antibody, Unconjugated, Clone 11C9 from Abcam
Biology Products: